Group 1 - Kailong High-Tech is focusing on the embodied intelligence sector, launching the "Huilingjia" series of robots and dexterous intelligent detection equipment, which are still in the market development stage and have not yet generated revenue [2] - Wuzhou New Spring plans to establish a joint venture with Zhongzhe High-Speed Rail, focusing on the research and manufacturing of high-end equipment bearings, with a registered capital of 60 million yuan [3] - GCL-Poly has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory stage, and this has not materially impacted the company's performance [5] Group 2 - Guoxuan High-Tech plans to raise no more than 5 billion yuan through a private placement, with proceeds allocated to a 20GWh power battery project and other related initiatives [4] - Xingsheng Zhitu confirmed that its operations are normal and there are no undisclosed significant matters [6] - Nanjin Mining intends to invest 30 million USD to acquire a 10% stake in Eagle Valley Gold Company, pending regulatory approvals [7] Group 3 - Lixun Precision plans to engage in foreign exchange derivatives trading for up to one year, with a cumulative limit of 4.9 billion USD [8] - Heng Rui Medicine's HR091506 tablet application for market approval has been accepted by the National Medical Products Administration, targeting long-term treatment for hyperuricemia in gout patients [11] - Wen's shares reported a revenue of 4.698 billion yuan from pork sales in January 2026, a decrease of 11.17% month-on-month [12] Group 4 - Yingjixin reported a net profit of 177 million yuan for 2025, a year-on-year increase of 42.81% [13] - Xibu Muye's fresh milk production in January 2026 was 3,076.65 tons, a year-on-year decrease of 2.54% [15] - Alibaba Health's shareholding in Shuyupingmin has decreased to 5.39% following a series of share reductions [16] Group 5 - Jiangfeng Electronics plans to acquire control of Kaide Quartz, with stock resuming trading on February 6 [17] - Runze Technology is planning to issue convertible bonds to acquire minority stakes in Runhui Technology, leading to a stock suspension starting February 6 [18] - Tianqimo is planning to purchase shares of Dongshi Automotive Technology Group, resulting in a stock suspension from February 6 [19] Group 6 - ST Lifang's stock has surged by 314.93% from January 20 to February 5, leading to a suspension for risk assessment [20][21]

Core Viewpoint - Heng Rui Medicine has received acceptance for its HR091506 tablet application from the National Medical Products Administration, aimed at long-term treatment of hyperuricemia in gout patients [1] Group 1 - The HR091506 tablet is developed using gastric retention formulation technology and features a pulsatile release characteristic [1] - The product consists of a rapid-release part and a delayed-release part, designed to quickly achieve effective blood drug concentration and maintain it over an extended period [1] - The goal of HR091506 is to improve the rate of achieving target uric acid levels in patients [1]

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

Group 1 - The core point of the article is that Heng Rui Medicine has received acceptance for its HR091506 tablet's market approval application from the National Medical Products Administration of China [1] - The application is based on two key Phase III clinical studies, HR091506-301 and HR091506-302, which evaluated the efficacy and safety of HR091506 in patients with gout and hyperuricemia [1] - The HR091506-301 study involved 442 participants across 73 centers, while the HR091506-302 study included 765 participants across 71 centers, both showing significant efficacy over the control group [1] Group 2 - HR091506 is a self-developed oral sustained-release tablet utilizing gastric retention technology, featuring both rapid and delayed release components [2] - The rapid-release part quickly achieves effective blood drug concentration, while the delayed-release part maintains the concentration over a longer period [2] - The total R&D investment for the HR091506 project has reached approximately 127 million yuan (unaudited) [2]

Core Viewpoint - Heng Rui Medicine (01276.HK) has received the acceptance notice from the National Medical Products Administration for the listing application of HR091506 tablets, indicating progress in its drug development pipeline [1] Group 1: Clinical Research - The listing application is based on two key Phase III clinical studies (HR091506-301 and HR091506-302) that are randomized, double-blind, and have a positive control with febuxostat [1] - The HR091506-301 study evaluated the efficacy and safety of HR091506 tablets in patients with gout and hyperuricemia requiring deep uric acid control, involving 442 subjects across 73 centers, led by Professors Zou Hejian and Xue Yu from Huashan Hospital, Fudan University [1] - The HR091506-302 study assessed the efficacy and safety of HR091506 tablets in patients with gout and hyperuricemia, enrolling 765 subjects across 71 centers, with Professor Zhang Zhuoli from Peking University First Hospital as the principal investigator [1] Group 2: Study Results - Results from both studies showed that HR091506 tablets significantly outperformed the control group on primary endpoints [1] - The long-term safety and tolerability of HR091506 tablets in patients with gout and hyperuricemia were found to be good [1]

Core Viewpoint - Heng Rui Medicine has received acceptance for the listing application of HR091506 tablets from the National Medical Products Administration, indicating progress in the drug's approval process [1] Group 1: Clinical Research - The listing application is based on two key Phase III clinical studies (HR091506-301 and HR091506-302) that are randomized, double-blind, and have a positive control with febuxostat [1] - The HR091506-301 study evaluated the efficacy and safety of HR091506 tablets in gout patients with high uric acid levels, involving 442 participants across 73 centers [1] - The HR091506-302 study also assessed the efficacy and safety of HR091506 tablets in gout patients, with 765 participants across 71 centers [1] - Both studies showed that HR091506 tablets significantly outperformed the control group on primary endpoints and demonstrated good long-term safety and tolerability in patients [1] Group 2: Product Development - HR091506 tablets are developed using gastric retention formulation technology, featuring a pulse release characteristic with both immediate and delayed release components [2] - The immediate release part quickly achieves effective blood drug concentration, while the delayed release part maintains the concentration over an extended period [2] - The total R&D investment for HR091506 tablets has reached approximately 127 million yuan (unaudited) [2]

Core Viewpoint - Heng Rui Medicine has received acceptance notification from the National Medical Products Administration for its HR091506 tablet, aimed at long-term treatment of hyperuricemia in gout patients [1] Group 1: Product Development - HR091506 is a self-developed oral sustained-release tablet utilizing gastric retention technology, featuring pulse release characteristics [1] - The product consists of a rapid-release part and a delayed-release part, designed to quickly achieve effective blood drug concentration and maintain it over an extended period [1] - The cumulative R&D investment for HR091506 has reached approximately 126.7 million yuan (unaudited) [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received acceptance from the National Medical Products Administration for its HR091506 tablet, aimed at long-term treatment of hyperuricemia in gout patients [1] Group 1: Product Development - HR091506 is a self-developed oral sustained-release tablet utilizing gastric retention technology, featuring pulse release characteristics [1] - The product consists of a rapid-release portion that quickly achieves effective blood drug concentration and a delayed-release portion that maintains drug concentration over time [1] - The total R&D investment for the HR091506 project has reached approximately 126.7 million yuan (unaudited) [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received the acceptance notice from the National Medical Products Administration for the listing application of HR091506 tablets, intended for the long-term treatment of hyperuricemia in gout patients [1] Group 1: Product Development - HR091506 tablets are developed using gastric retention formulation technology and feature a pulsatile release characteristic, consisting of both immediate-release and delayed-release components [1] - The immediate-release part quickly releases in the stomach to achieve effective blood drug concentration, while the delayed-release part remains in the stomach to sustain the release, aiming to prolong the maintenance time of effective blood drug concentration and improve the rate of achieving uric acid reduction targets [1] - The total R&D investment for the HR091506 project has reached approximately 126.7 million yuan (unaudited) [1]

Core Viewpoint - The company has received acceptance from the National Medical Products Administration for the marketing authorization application of HR091506 tablets, a novel oral sustained-release formulation of febuxostat [1] Group 1: Product Development - HR091506 tablets are developed using gastric retention formulation technology and feature a pulsatile release characteristic [1] - The product consists of a rapid-release component and a delayed-release component, designed to quickly achieve effective blood drug concentration and maintain it over an extended period [1] Group 2: Market Implications - The sustained-release nature of HR091506 aims to improve the rate of achieving target uric acid levels in patients [1]